XFOR earnings

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, and highlighted key recent events and expected upcoming milestones. "The first quarter of 2025 was an

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Foll

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome 2024 XOLREMDI® net revenues $2.6 million since May launch; company expects ramp up in 2025 as targeted physician outreach increases patient finding and pull-through Conference call and webcast today at 8:30 am ET BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www

Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of XOLREMDI® (mavorixafor) in WHIM underway; submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) expected by early 2025 Conference call and webcast today at 8:00 a.m. ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent and key upcoming ex

Mavorixafor durably and meaningfully elevated participants' mean absolute neutrophil counts (ANC) Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal levels Phase 2 study results and new analysis confirming functionality of neutrophils in sub-study participants bolster confidence in achieving success in Phase 3 4WARD trial Company conference call and webcast today at 8:00 am ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced positive new clinical data from its now completed Phase 2 clinical trial evaluating mav

BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024. The company will host a conference call and webcast on the same day at 8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accom

First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in November 2024 Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia Conference call to be hosted today at 8:30 a.m. ET BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the second quarter ended June 30, 2024 and highlighted key recent and upcoming expected milestones. Paula Ragan, Ph.D., President and Chief Executi

BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the second quarter ended June 30, 2024 and provide corporate updates on Thursday, August 8, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-225-9448 from the United States or 1-203-518-9708 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.co

U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial in chronic neutropenia expected at a planned company investor event in June 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and hig

BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13745487. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4phar

XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with approval Conference call and webcast to be hosted today at 8:30 am ET BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemi

Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 Additional Phase 2 clinical data and initiation of global Phase 3 clinical trial of mavorixafor for the treatment of certain chronic neutropenic disorders expected in 1H24 Conference call to be hosted today at 8:30 a.m. ET BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted key 2023 events and expected upcomin

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13744107. The live webcast will be accessible through the investor relations section of X4 Pharmaceutical

U.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if approved Presentations of additional data from ongoing Phase 2 clinical trial of mavorixafor in chronic neutropenia expected in 4Q 2023 and 1H 2024 Pivotal, global Phase 3 trial of mavorixafor in chronic neutropenia expected to initiate in 1H 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2023 and providing corporate updates on Thursday, November 9, 2023. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13741400. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at w

Submission of first U.S. New Drug Application for mavorixafor in WHIM syndrome on track for early 2H 2023 Emerging data from ongoing Phase 2 trial in certain chronic neutropenic disorders show mavorixafor durably increased neutrophil counts and enabled reductions in G-CSF dosing New market research confirms significant initial target population for mavorixafor given high unmet needs within U.S. chronic neutropenia (CN) market Plans underway for initiation of Phase 3 trial in certain chronic neutropenic disorders in 1H 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a leader in the discovery and develo

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the second quarter ended June 30, 2023, and providing corporate and clinical program updates on Thursday, August 10, 2023. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13739751. The live webcast and accompanying slide present

Company to host webinar event on May 16th presenting new clinical data from the4WHIM Phase 3 trial; oral presentation to follow on May 21st at the 2023Clinical Immunology Society (CIS) Annual Meeting U.S. NDA submission of mavorixafor for WHIM syndrome on track for early 2H 2023 Presentation of data from ongoing Phase 2 chronic neutropenia trial and clarity on regulatory path forward anticipated in 2Q/3Q 2023 Conference call to be hosted today at 8:30 a.m. ET BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported fi

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023. The company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and recent business highlights. The conference call can be accessed by dialing 1-855-327-6837 from the United States or 1-631-891-4304 internationally, followed by the conference ID: 10021600. The live webcast can be accessed on th

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023. The company will host a conference call and webcast on the same day at 9:00 a.m. ET to discuss these financial results and recent business highlights. The conference call can be accessed by dialing 1-855-327-6837 from the United States or 1-631-576-4098 internationally, followed by the conference ID: 10020997. The live webcast can be

4WHIM trial meets primary endpoint and first key secondary endpoint, with mavorixafor achieving statistically significant and clinically relevant longer times above threshold levels for both absolute neutrophil (P <0.0001) and absolute lymphocyte counts (P<0.0001) versus placebo Mavorixafor was generally well tolerated in the trial Company to host a conference call and webcast today at 4:30 p.m. ET BOSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) --  X4 Pharmaceuticals (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced positive top-line results from the global, pivotal Phase 3 clinical

Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the fourth quarter of 2022 Conference call to be hosted today at 8:30 a.m. ET BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent and upcoming expected milestones. "This is a truly exciting time for X4 as we near the announcement of top-li

BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2022 on November 3, 2022. X4 will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss important upcoming milestones, including the pending release of results from the company's Phase 3 trial of its lead candidate mavorixafor in the treatment of WHIM syndrome. The conference call can be accessed by dialing 1-855-327-6837 from the United States or 1-

Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global, pivotal Phase 3 trial in WHIM syndrome, expected in 4Q 2022 Announces additional positive data from Phase 1b trial in Waldenström's Macroglobulinemia supportive of a potential partnership to advance clinical development Conference call to be hosted today at 8:30 a.m. EDT BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial resul

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the second quarter ended June 30, 2022, and provide an update on recent business highlights, on August 4, 2022. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing 1-855-327-6837 from the United States or 1-631-891-4304 internationally, followed by the conference

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22 Clinical and regulatory updates from ongoing chronic neutropenia Phase 1b study anticipated during 3Q 2022; Waldenström's macroglobulinemia Phase 1b study now fully enrolled with results expected in second half of 2022 Conference call to be hosted today at 8:30 a.m. EDT BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, (NASDAQ:XFOR), a leader in the discovery and development of novel oral CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today reported financial results for the first quarter ended March 31, 2022. "As we quickly appro

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that it will report its financial results for the first quarter ended March 31, 2022, and provide an update on recent business highlights, on May 12, 2022. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID:

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22 Clinical and regulatory updates from ongoing chronic neutropenia Phase 1b trial anticipated during 2Q/3Q 2022 Additional Waldenström's macroglobulinemia Phase 1b data expected in second half of 2022; supportive pre-clinical data to be presented at AACR 2022 Conference call today at 8:30 a.m. EDT BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the fourth qua

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the fourth quarter ended December 31, 2021, and provide an update on recent business highlights, on March 17, 2022. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the confer

Data continue to support mavorixafor's potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenström's macroglobulinemia Discovery of new prevalent WHIM variant further validates the company's U.S. WHIM prevalence projections Company to host an Investor Day on December 16 with key opinion leaders leading discussions on four poster presentations and additional clinical and scientific data Conference call today at 9:05 a.m. ET BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today r

BOSTON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the third quarter ended September 30, 2021, and provide an update on recent business highlights, on November 4, 2021. The company will host a conference call and webcast on the same day at 9:05 a.m. ET to discuss these financial results and business highlights. The company also anticipates discussion of abstracts accepted to the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and ex

Twenty-three patients now enrolled in ongoing pivotal Phase 3 trial in WHIM syndrome, surpassing minimum needed for primary endpoint analyses; enrollment to complete in 3Q21 with top-line data expected in 4Q22 Minimum number of patients now enrolled to determine optimal dosing of mavorixafor in Waldenström's macroglobulinemia Phase 1b trial; continue to expect high-dose safety and efficacy data, as well as clinical response outcomes, in 4Q21 Initial data from Phase 1b trial in Severe Congenital Neutropenia (SCN) expected in 4Q21, as company explores expanded use of mavorixafor across broader chronic neutropenia populations Conference call today at 8:30 a.m. ET BOSTON, Aug. 03, 2021 (GL

BOSTON, July 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2021, and provide an update on recent business highlights, on August 3, 2021. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 2236266. The